CryoSeal nears $125m US fibrin sealant market
This article was originally published in Clinica
ThermoGenesis says that enrolment is now complete for its 150-patient US pivotal trial evaluating the safety and efficacy of its CryoSeal fibrin sealant system in liver resection surgery. The company will use the data in support of a premarket approval (PMA) application to the US FDA, which is expected by the end of 2005; approval is set to follow in 2006.
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.